The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

CD3 antibodies are proven immunosuppressants capable of reversing transplant rejection episodes. Their general application has been limited both by their immunogenicity and, in particular, by the “first‐dose” cytokine‐release syndrome experienced by patients after the initial administration of antibody. We have produced a set of variants of the humanized YTH 12.5 CD3 monoclonal antibody (mAb) (Routledge et al., Eur. J. Immunol. 1991. 21: 2717) bearing different human heavy (H) chain constant regions, with the intention of finding a form of the antibody that is not able to activate T cells. Comparison of the variants having γl, γ2, γ3 and γ4 H chains in a competitive binding assay showed that antibody avidity was not affected by IgG subclass. Using a sensitive indicator of FcR binding activity (the capacity of the CD3 mAb to redirect cytotoxic T cells to kill the monocytic cell line U‐937) we demonstrated a functional hierarchy of γl = γ4 α2 = γ3 mb > γ2. An aglycosyl version of the γl CD3 mAb, produced by site‐directed mutagenesis (Asn297 to Ala), still had considerable activity in this assay (intermediate to the γl and α2 CD3 mAb), albeit at a level approximately 10‐fold lower than that of the parental γl form. When we tested their ablity to stimulate T cell proliferation in vitro in the presence of 5% human serum, all of the wild‐type immunoglobulin isotypes were found to be active, although there were T cell donor‐dependent variations in the extent of the responses. The aglycosyl γl mAb was, however, completely non‐mitogenic in all of ten donors tested, unless the assay was performed in IgG‐free medium. Despite being non‐stimulatory, this mAb was also able to inhibit the mixed lymphocyte reaction responses of both naive and primed T cells. Comparison of the yl and aglycosyl γ1 mAb in an experimental mouse model for CD3 mAb‐induced cytokine release indicated that removal of the carbohydrate moiety from the γl constant region reduced the in vivo tumor necrosis factor‐a response by a factor of at least 16‐fold. These data suggest that the aglycosyl γl CD3 mAb is a promising candidate for immunosuppressive therapy without “first dose” side effects.

[1]  J. Bluestone,et al.  Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. , 1992, Journal of immunology.

[2]  J. Isaacs,et al.  Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. , 1992, Journal of immunology.

[3]  S. D. Gorman,et al.  A humanized monovalent CD3 antibody which can activate homologous complement , 1991, European journal of immunology.

[4]  J. V. D. van de Winkel,et al.  A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. , 1991, Journal of immunology.

[5]  J. Bluestone,et al.  Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. , 1991, Transplantation proceedings.

[6]  C. Ferran,et al.  Anti-TNF abrogates the cytokine-related anti-CD3 induced syndrome. , 1991, Transplantation proceedings.

[7]  P. Garred,et al.  Human IgG subclass pattern of inducing complement‐mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration , 1991, European journal of immunology.

[8]  A. Tunnacliffe,et al.  Structure of the T cell antigen receptor (TCR): two CD3 epsilon subunits in a functional TCR/CD3 complex , 1991, The Journal of experimental medicine.

[9]  P. Tan,et al.  Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen , 1990, The Journal of experimental medicine.

[10]  R. Jefferis,et al.  Molecular definition of interaction sites on human IgG for Fc receptors (huFcγR) , 1990 .

[11]  R. V. van Lier,et al.  Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. , 1990, Transplantation.

[12]  G. Sármay,et al.  A protein structural change in aglycosylated IgG3 correlates with loss of huFcγR1 and hufcγR111 binding and/or activation , 1990 .

[13]  L. Chatenoud,et al.  Monoclonal antibodies to CD3 as immunosuppressants. , 1990, Seminars in immunology.

[14]  P. Vandenabeele,et al.  Hypothermia and hypoglycemia induced by anti‐CD3 monoclonal antibody in mice: Role of tumor necrosis factor , 1990, European journal of immunology.

[15]  J. Bluestone,et al.  Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation , 1990, European journal of immunology.

[16]  S L Morrison,et al.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.

[17]  C. Ferran,et al.  Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. , 1989, The New England journal of medicine.

[18]  P. Vereerstraeten,et al.  RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.

[19]  B. Seed,et al.  Isolation and expression of functional high-affinity Fc receptor complementary DNAs. , 1989, Science.

[20]  J. Bluestone,et al.  In vivo administration of anti-CD3 prevents malignant progressor tumor growth. , 1988, Science.

[21]  J. Yodoi,et al.  Regulation of Fc epsilon R2/CD23 gene expression by cytokines and specific ligands (IgE and anti-Fc epsilon R2 monoclonal antibody). Variable regulation depending on the cell types. , 1988, Journal of immunology.

[22]  J. Bluestone,et al.  Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. , 1988, Journal of immunology.

[23]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[24]  L. Kedes,et al.  A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Pinsky,et al.  Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. , 1987, Transplantation proceedings.

[26]  B. Markus,et al.  Impact of Orthoclone OKT3 on liver transplantation. , 1987, Transplantation proceedings.

[27]  R. Klausner,et al.  A new subunit of the human T-cell antigen receptor complex , 1986, Nature.

[28]  M. Crumpton,et al.  Primary structure of the T3 gamma subunit of the T3/T cell antigen receptor complex deduced from cDNA sequences: evolution of the T3 gamma and delta subunits. , 1986, The EMBO journal.

[29]  C. June,et al.  Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. , 1986, Journal of immunology.

[30]  J. Coligan,et al.  Isolation of cDNA clones encoding the 20K non-glycosylated polypeptide chain of the human T-cell receptor/T3 complex , 1986, Nature.

[31]  R. Colvin,et al.  Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. , 1986, Transplantation.

[32]  M. Lefranc,et al.  Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C gamma genes. , 1986, Nucleic acids research.

[33]  N. Dunlap,et al.  Analysis of the monocyte Fc receptors and antibody-mediated cellular interactions required for the induction of T cell proliferation by anti-T3 antibodies. , 1985, Journal of immunology.

[34]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[35]  Robert O. Fox,et al.  Recombinant antibodies possessing novel effector functions , 1984, Nature.

[36]  J. Flanagan,et al.  Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ, ε and α genes , 1982, Nature.

[37]  T. Honjo,et al.  Structure of human immunoglobulin gamma genes: implications for evolution of a gene family , 1982, Cell.

[38]  J. Flanagan,et al.  The sequence of a human immunoglobulin epsilon heavy chain constant region gene, and evidence for three non‐allelic genes. , 1982, The EMBO journal.

[39]  C. Milstein,et al.  Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell lines , 1981, Somatic cell genetics.

[40]  R. Colvin,et al.  Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. , 1981, The New England journal of medicine.

[41]  G. Gifford,et al.  Purification and physico-chemical characterization of rabbit tumor necrosis factor. , 1980, Journal of immunology.

[42]  L. Aller.  Astrophysical Quantities. C. W. Allen Oxford University Press, New York, ed. 2, 1963. xii + 291 pp. Illus. $ 10.10 , 1963 .

[43]  C. Milstein,et al.  An oscillating bubble chamber for laboratory scale production of monoclonal antibodies as an alternative to ascitic tumours. , 1992, Journal of immunological methods.

[44]  M. Page,et al.  High Level Expression of the Humanized Monoclonal Antibody CAMPATH-1H in Chinese Hamster Ovary Cells , 1991, Bio/Technology.

[45]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[46]  R. Jefferis.  6 – Structure–function relationships of IgG subclasses , 1990 .

[47]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[48]  R. V. van Lier,et al.  Induction of T cell proliferation with anti‐CD3 switch‐variant monoclonal antibodies: effects of heavy chain isotype in monocyte‐dependent systems , 1987, European journal of immunology.

[49]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[50]  P. Beverley,et al.  T cell activation by anti‐T3 antibodies: Comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors , 1986, European journal of immunology.

[51]  M. Bevan,et al.  Cytotoxic T lymphocyte‐mediated lysis via the Fc receptor of target cells , 1985, European journal of immunology.

[52]  S. Orkin,et al.  Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex , 1984, Nature.

[53]  H. Spiegelberg,et al.  Structure and function of Fc receptors for IgE on lymphocytes, monocytes, and macrophages. , 1984, Advances in immunology.

[54]  L. Chatenoud,et al.  Human in vivo antigenic modulation induced by the anti‐T cell OKT3 monoclonal antibody , 1982, European journal of immunology.